Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin ± taxane-pretreated ovarian cancer patients

Annals of Oncology

Volumn 13, Issue 2, 2002, Pages 258-266

  Dieras, V ^a   Bougnoux, P ^b   Petit, T ^c   Chollet, P ^d   Beuzeboc, P ^a   Borel, C ^c   Husseini, F ^e   Goupil, A ^f   Kebrat, P ^g   Misset, J L ^h   Bensmaine M A ⁱ   Tabah Fisch, I ^j   Pouillart, P ^a  

^a INSTITUT CURIE   (France)

^b CHU BRETONNEAU   (France)

^c CENTRE PAUL STRAUSS   (France)

^d Surgical Department   (France)

^e Hospitaux Civils   (France)

^f CENTRE RENÉ HUGUENIN   (France)

^g CENTRE EUGÈNE MARQUIS   (France)

^h HÔPITAL PAUL BROUSSE   (France)

ⁱ Cvitkovic et Associes Consultants   (France)

^j SANOFI   (France)

more..

Author keywords

Diaminocyclohexane platinum; Neurotoxicity; Salvage chemotheraphy; Taxanes

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; OXALIPLATIN; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LIVER METASTASIS; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOMATOSENSORY DISORDER; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0036299552     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf018     Document Type: Article

References (40)

1. The chemotherapy of ovarian cancer
2. Epidemiology of ovarian cancer
3. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
4. Is cisplatin-taxol (PT) the standard treatment in advanced ovarian cancer?
5. Second-line platinum therapy in patients with previously treated with cisplatin
6. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma
7. Phase II trial of vinblastine in previously treated patients with ovarian cancer
8. Ovarian cancer
9. 1,2-Diaminocyclohexane platinum derivatives of potential clinical values
10. Oxaliplatin: A review of preclinical and clinical studies
11. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin
12. Cross-resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analogues
13. Oxalatoplatinum (L-OHP): Experimental and clinical studies
14. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
15. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin
16. The clinical relevance of mismatch repair protein immunohistochemistry in ovarian cancer
17. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease
18. Grading of toxicity
19. Reporting results of cancer treatment
20. Response to salvage chemotherapy in ovarian cancer: A critical need for precise definition of the treated population
21. Phase II of docetaxel in patients with platinum refractory ovarian cancer
22. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients
23. Phase I study of oxaliplatin in patients with advanced cancer
24. Oxaliplatin (L-OHP): Global safety in 682 patients (pts)
25. Phase II trial of oxaliplatin as first line chemotherapy in metastatic colorectal cancer patients
26. Multicentric phase II-III trial of oxaliplatin (LOHP) versus cisplatin (P) both in association with cyclophosphamide (C) in the treatment of advanced ovarian cancer (AOC): Toxicity and efficacy results
27. Paclitaxel for platinum refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute treatment referral centre 9103
28. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label, phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
29. A phase II study of paclitaxel in platinum pretreated ovarian cancer
30. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
31. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
32. Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: Results of a large European phase II study
33. Paclitaxel (taxol) in heavily pretreated ovarian cancer: Antitumoral activity and complications
34. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
35. In vitro and in vivo rationale for oxaliplatin in combination with other antitumor agents
36. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer
37. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group
38. Multicenter randomized Phase II study of oxaliplatin (OXA) or topotecan (TOPO) in platinum-pretreated epithelial ovarian cancer (EOC) patients (pts)
39. Feasibility study of the paclitaxel (PXL), oxaliplatin (LOHP) and ciplatin (CDDP) combination in advanced ovarian cancer (AOC)
40. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate use experience